Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
The European Journal of Health Economics
Published in: The European Journal of Health Economics 1/2013

01-02-2013 | Original Paper

Valuing EQ-5D using Time Trade-Off in France

Authors: Julie Chevalier, Gérard de Pouvourville

Published in: The European Journal of Health Economics | Issue 1/2013

Login to get access

Abstract

Objectives

While a French language version of the EQ-5D exists, to date, there has been no French value set to accompany it. The objective of our study was then to derive the French TTO value set of the EQ-5D.

Methods

A total of 452 respondents aged over 18 were recruited who were representative of the French population with regard to age, gender, and socio-professional group. The direct valuation of 24 health states was first obtained by Time Trade-Off (TTO), and the negative TTO values were bounded using the monotonic transformation. Several alternative model specifications were investigated to estimate the values for all 243 states in the EQ-5D descriptive system. Only the best fitting model is presented in this paper. The analysis was conducted at an individual level to make the maximum use of the available data, and we estimated mixed models with random intercept. Models were compared through the Akaike information criterion (AIC), the mean absolute error (MAE), and the Pearson correlation coefficient between the observed and the predicted values of each model.

Results

After exclusion, 443 respondents took part in the study. The best fitting model included the same variables as the N3-model used in UK.

Conclusion

This study provides the French value set of the EQ-5D based on the stated preferences of the French general public facilitating cost-effectiveness analysis.
Literature
1.
Brooks, R.: EuroQoL: the current state of play. Health Policy 1, 53–72 (1996)CrossRef
2.
Torrance, G.W., Boyle, M.H., Horwood, S.P.: Application of multi-attribute theory to measure social preferences for health states. Oper. Res. 6, 1043–1069 (1982)CrossRef
3.
Ware, J.E., Sherbourne, C.D.: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med. Care 6, 473–483 (1992)CrossRef
4.
Le Galès, C., Buron, C., Costet, N., et al.: Développement d’un index d’états de santé pondéré par les utilités en population française: le health utilities index. Econ. Prev. 150, 71–87 (2001)
5.
Collège des Économistes de la Santé: Guide méthodologique pour l’évaluation économique des stratégies de santé. Recommandations méthodologiques. Paris (2003)
6.
Haute Autorité de Santé: L’évaluation économique à la Haute Autorité de Santé Principes et méthodes. Paris (2010)
7.
Adam, P., Herzlich, C.: Sociologie de la maladie et de la médecine. Armand Colin (2007)
8.
Johnson, J.A., Ohinmaa, A., Murti, B., et al.: Comparison of Finnish and U.S.-based visual analog scale valuations of the EQ-5D measure. Med. Decis. Making 20, 281–289 (2000)PubMedCrossRef
9.
Johnson, J.A., Luo, N., Shaw, J., et al.: Valuations of EQ-5D health states: are the United States and United Kingdom different? Med. Care 43, 221–228 (2005)PubMedCrossRef
10.
Lamers, L.M., McDonnell, J., Stalmeier, P., et al.: The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies. Health Econ. 15, 1121–1132 (2006)PubMedCrossRef
11.
Golicki, D., Jakubczyk, M., Niewada, M., et al.: Valuations of EQ-5D health states in Poland: first TTO-based social value set in Central and Eastern Europe. Value Health 13, 289–297 (2010)PubMedCrossRef
12.
Dolan, P.: Modeling valuations for EuroQol health states. Med. Care 11, 1095–1108 (1997)CrossRef
13.
Macran, S., Kind, P.: Valuing EQ-5D health states using a modified MVH protocol: preliminary results. In: Badia, X., Herdman, M., Roset, M. (eds.) Proceedings of the 16th Plenary Meeting of the EuroQol Group, pp. 205–240. Institut de Salut Publica de Catalunya (2000)
14.
Tsuchiya, A., Ikeda, S., Ikegami, N., et al.: Estimating an EQ-5D population value-set: the case of Japan. Health Econ. 4, 341–353 (2002)CrossRef
15.
Parkin, D., Devlin, N., Sharma, P.: A deathless and VAS-free EQ-5D self-completion valuation questionnaire. In: Stavem, K. (ed.) Proceedings of the 22nd Plenary Meeting of the EuroQol Group, Oslo, pp. 170–189 (2005)
16.
Szende, A., Oppe, M., Devlin, N.: EQ-5D value sets. Inventory, comparative review and user guide. Springer, Dordrecht (2007)CrossRef
17.
Lamers, L.M.: The transformation of utilities for health states worse than death: consequences for the estimation of EQ-5D value-sets. Med. Care 3, 238–244 (2007)CrossRef
18.
Shaw, J.W., Johnson, J.A., Coons, S.J.: US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med. Care 3, 203–220 (2005)CrossRef
19.
Chuang, L.H., Kind, P.: The effect of health state selection on the valuation of EQ-5D. Med. Decis. Making 31, 186–194 (2010)PubMedCrossRef
20.
O’Brien, B.J., Drummond, M.F.: Statistical versus quantitative significance in the socioeconomic evaluation of medicines. Pharmacoeconomics 5, 389–398 (1994)PubMedCrossRef
21.
Devlin, N.J., Hansen, P., Kind, P., et al.: Logical inconsistencies in survey respondents’ health state valuations—a methodological challenge for estimating social tariffs. Health Econ. 7, 529–544 (2003)CrossRef
Metadata
Title
Valuing EQ-5D using Time Trade-Off in France
Authors
Julie Chevalier
Gérard de Pouvourville
Publication date
01-02-2013
Publisher
Springer-Verlag
Published in
The European Journal of Health Economics / Issue 1/2013
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-011-0351-x

Other articles of this Issue 1/2013

The European Journal of Health Economics 1/2013 Go to the issue

Original Paper

The impact of new (orphan) drug approvals on premature mortality from rare diseases in the United States and France, 1999–2007

Original Paper

Is health care a luxury or a necessity or both? Evidence from Turkey

Original Paper

Federal state differentials in the efficiency of health production in Germany: an artifact of spatial dependence?

Original Paper

Body weight and health-related quality of life in Catalonia, Spain

Original Paper

What can we learn from international comparisons of costs by DRG?

Original Paper

Key issues in the design of pay for performance programs